Organisation paid for research Program year 2020 Source: CMS Open Payments

CNS Research Science Inc

Neither a doctor nor a teaching hospital

Research payments

$791,607

49 payments

Through program year 2020, CNS Research Science Inc is reported as receiving $791,607 in research payments, across 49 payments.

By program year

2 rows
Year Kind Amount Payments
2020 Research $13,170 33
2019 Research $778,437 16

Breakdown

Who paid Research payments · program years 2019–2020
  1. Otsuka Pharmaceutical Development & Commercialization, Inc. $760,079 4 payments
  2. ACADIA Pharmaceuticals Inc $11,086 25 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $10,253 5 payments
  4. H. Lundbeck A S $8,079 6 payments
  5. Eli Lilly and Company $1,000 1 payment
  6. ITI, Inc. $899 5 payments
  7. Alkermes, Inc. $210 3 payments
Studies the money was for Research payments · program years 2019–2020
  1. Protocol 331-201-00081 A Multicenter, Randomized, Double-Blind Trial of Brexpiprazole Versus Placebo for the Acute Treatment of Manic Episodes, With Or Without Mixed Features, Associated With Bipolar I Disorder $698,683 2 payments
  2. A Multicenter, Open-Label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Bipolar I Disorder $61,396 2 payments
  3. Acp-103-034 $11,086 25 payments
  4. A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine 5, 10 and 20 mg in Adults With Major Depressive Disorder $10,253 5 payments
  5. Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia DayBreak $5,000 2 payments
  6. Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia (Debut) $2,000 2 payments
  7. Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia Debut $1,079 2 payments
  8. An Open Label, Long Term, Safety Study of Lasmiditan 100 MG and 200 MG in the Acute Treatment of Migraine Gladiator $1,000 1 payment
  9. An Open-Label, MultiCenter Trial to Assess the Safety and Effectiveness of ITI-007 in Patients with Schizophrenia $899 5 payments
  10. A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder $210 3 payments
What the money was spent on Research payments · program years 2019–2020
  1. Other $10,253 5 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2020

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record